“Funds raised in November provide capital to take the company towards profitability and we continue to invest in the pipeline, manufacturing and commercial platforms,” CEO JIm Phillips.
Showing 25 of 1310
It completed its long-mooted listing on Nasdaq where, some would argue, pharmaceutical companies (and how to value them) are better understood.
The company will use an exclusive license it is acquiring for a new paraben-free technology for the task.
The firm purchased topical products for the relief of diabetic neuropathy symptoms via its earlier acquisition of Cincinatti-based 40Js.
The money will be used to pay down some of its US$30mln debt
District Judge Sue Robinson in Delaware announced a ban on Regeneron and Sanofi from selling their cholesterol drug, Praluent on the grounds of patent infringement.
The strategy will reduce development costs and open up multiple marketing avenues addressing different market segments.
Revenues are on the rise and the group’s efforts to bring in new business is delivering.
The company is developing ImMucin, which targets MUC-1, a unique cancer antigen with high specificity to malignant cells, and results in a potent stimulation effect on T and B cells.
"Jasmine's depth of experience in driving corporate IP strategies and business development, as well as bringing products to market in Asia, will be a huge asset to Volition," said CEO Cameron Reynolds.
Dr H Lee Sweeney, who led the research, said: "There remains a large unmet need in Duchenne for therapies that can treat all affected boys and slow disease progression.
Vocera solutions provide hands-free voice communication, secure text messaging, patient engagement tools, and integrated clinical work flow
VolitionRx Limited (NYSEMKT:VNRX) shares jumped 4.4% on Tuesday after the company said it achieved CE marking on its Nu.QTM Colorectal Cancer Screening Triage Test on December 28, paving the way for its expected launch across the European Union.
J&J abruptly bowed out of the bid process for Actelion last week after the Swiss firm said that it was “engaged in discussions with another party”.
Nasdaq-listed Incyte is taking a big bet on the potential for bispecific antibodies in biotherapeutics
Glaxo has developed the new two-drug cocktail through its majority-owned ViiV Healthcare joint venture, in which US firm Pfizer and Japan’s Shionogi also hold stakes.
Akers Bio estimates that a typical hospital can save up to US$1mln annually using its test
Pressure BioSciences, Inc sees itself playing a key role in the US $1.8bn “Cancer Moonshot” initiative after legislation was signed this week, according to a statement on Friday
Third quarter numbers do not reflect what a blockbuster quarter Summit enjoyed
Plazomicin was well tolerated with no new safety concerns identified
In a statement, the CMA said Pfizer ramped up the price of phenytoin sodium capsules by 2,600%
The drug is being developed to treat gastroparesis - a condition where the stomach does not empty itself in the normal way.
In two types of epilepsy, Dravet Syndrome and Lennox-Gastaut Syndrome, Epidiolex reduced the number of seizures compared to the placebo
The shares shot up as rebadged versions of the company's cholesterol checking kit look set to be sold over the counter in major US retailers
Vaxil is testing Immucin in combination with other immunotherapy modalities